SCHEMBL30714239

SCHEMBL30714239

OC1CCSc2ccc(Br)cc21

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.39
CA2 P00918 2/20 0.37
NPC1 O15118 1/20 0.35
CTSL P07711 1/20 0.35
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
RAB9A P51151 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
LMNA P02545 2/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
PTGDR Q13258 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3747979 1.00 BACE1 (0.39) BACE1CA2NPC1CTSLHTR2A
SCHEMBL631582 0.81 RAB9A (0.33) BACE1CTSLHTR2AHTR2CHTR2B
SCHEMBL13081103 0.79 CA2 (0.37) CA2NPC1
SCHEMBL18293058 0.79 HTR2A (0.42) BACE1CA2NPC1CTSLHTR2A
SCHEMBL18289387 0.79 KDM1A (0.35) BACE1NPC1CTSLHTR2AHTR2C
SCHEMBL2225883 0.77 NOS3 (0.34) BACE1NPC1CTSLHTR2AHTR2C
SCHEMBL23704910 0.76 CAMK2A (0.32) CTSLHTR2AHTR2CNOS3NOS1
SCHEMBL12290959 0.75 CTSL (0.33) BACE1CTSLRAB9AMAPT
SCHEMBL18293084 0.75 NPC1 (0.39) BACE1NPC1CTSLMEN1KMT2A
SCHEMBL18289370 0.75 HTR2A (0.33) BACE1NPC1CTSLHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025136671-A1 ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
EP-4540230-A1 ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF Ensem Therapeutics, Inc. (US) 2025-04-23 EP disclosed
US-20240246950-A1 Anilino-Pyrazole Derivatives, Compositions and Methods Thereof Ensem Therapeutics (US) 2024-07-25 US disclosed
WO-2023244710-A1 ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246950-A1 Anilino-Pyrazole Derivatives, Compositions and Methods Thereof CDK2, CDK3, CDK4 BACE1 2946/4885CA2 2628/4885NPC1 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.